Tag: Hormones: Misc.
Rates of Obesity, Weight Gain Up for Transmasculine Individuals
Prevalence of obesity and weight gain higher after hormone therapy for transmasculine versus transfeminine individuals
Five-Year Extended Hormone Therapy No Better in Breast Cancer
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone-receptor-positive breast cancer
Erythropoietin May Up Risk for Hip Fracture in Hemodialysis Patients
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and ≥300 versus <50 units/kg/week
Effect of COVID-19 on Breast Cancer Treatment Examined
More patients with estrogen receptor-positive, HER2-negative breast cancer treated with neoadjuvant endocrine therapy due to COVID-19
Fertility Concerns Impact Treatment Decisions in Breast Cancer
One-third of young women with breast cancer indicated that fertility concerns affected decisions relating to endocrine therapy
AHA Offers Guidance for CVD Risk in Breast, Prostate Cancer
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors
Gender-Affirming Hormone Therapy Tied to Systolic BP Changes
Within two to four months, increases, decreases in systolic BP seen in transmasculine, transfeminine adults, respectively
Study Explores Oxytocin Use in Active Phase of Induced Labor
Discontinuation of oxytocin may lead to small increase in rate of cesarean section, decrease in fetal heart rate abnormalities
Prolonged High-Dose Cyproterone Acetate Use Linked to Risk for Meningioma
Risk increased for meningiomas treated with surgery or radiotherapy; risk decreased after discontinuation of treatment
Primary Aldosteronism Testing Rare in Treatment-Resistant HTN
Testing correlated with increased likelihood of initiation of MRA therapy and with better BP control over time
